AstraZeneca's Tagrisso-Chemo Combo Under FDA Priority Review For Most Common Form Of Lung Cancer
Portfolio Pulse from Vandana Singh
AstraZeneca's supplemental New Drug Application for Tagrisso in combination with chemotherapy has been granted Priority Review by the FDA for locally advanced or metastatic non-small cell lung cancer (NSCLC). The FDA decision is expected in Q1 2024. The application is based on data from the FLAURA2 Phase 3 trial, which showed that the combination reduced the risk of disease progression or death by 38% compared to Tagrisso alone. AstraZeneca's shares are up 0.04% at $67.36.
October 16, 2023 | 2:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AstraZeneca's Tagrisso-chemo combo has been granted FDA Priority Review, potentially leading to a new revenue stream if approved. The company's shares are slightly up.
The FDA Priority Review for AstraZeneca's Tagrisso-chemo combo indicates a positive regulatory outlook, which could lead to approval and a new revenue stream for the company. This news is directly relevant to AstraZeneca and important for investors as it could impact the company's future earnings. The slight increase in the company's share price reflects the market's positive reaction to this news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100